NEW OPPORTUNITIES TO IMPROVE THE QUALITY AND DURATION OF LIFE IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
- Authors: Oganov R.1
-
Affiliations:
- National Research Center for Preventive Medicine
- Issue: Vol 28, No 1 (2017)
- Pages: 57-60
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116828
- ID: 116828
Cite item
Open Access
Access granted
Abstract
The paper discusses the issues of treating stable coronary heart disease: such as the signs and etiology of the disease, predictors of poor prognosis, international guidelines for treatment. The paper considers the principles of optimal therapy that includes medications to alleviate symptoms, to relieve pain, and to prevent complications. The mechanisms of action of the antianginal drug nicorandil are given. It is concluded that it is appropriate to more frequently use nicorandil in the therapy of various clinical manifestations of coronary heart disease.
Keywords
Full Text
About the authors
R. Oganov
National Research Center for Preventive Medicine
Email: roganov@gnicpm.ru
Professor, MD, Academician of the Russian Academy of Sciences
References
- FOX К., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris // Eur. Heart J. - 2006; 27: 1341-81.
- Montalescot G., Sechtem U., Aschenbach S. et al. 2013 ESC Guidelines on the management of stable coronary disease // Eur. Heart J. - 2013; 34: 29493003.
- Marzilli M., Merz C., Boden W. et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! // J. Am. Coll. Cardiol. - 2012; 60: 951-6.
- Ford E., Ajani U., Croft J. et al. Expending the disease in the US deaths from Coronary Disease 1980-2000 // N. Engl. J. Med. - 2007; 256: 2388-98.
- Карпов Ю.А. Активатор калиевых каналов никорандил: новые возможности терапии ишемической болезни сердца // Атмосфера. Новости кардиологии. - 2012; 3: 29-33.
- Гиляревский CP., Резван В.В., Кузьмина И.М. и др. Современные подходы к противоишемической терапии больных со стабильным течением ишемической болезни сердца // Мед. алфавит. - 2013; 2: 2-7.
- Булахова Е.Ю., Кореннова О.Ю., Кондрашева М.Н. и др. Клинические преимущества терапии никорандилом в сравнении с изосорбид-5-мононитратом у больных ИБС // Сердце. - 2013; 2 (70): 83-7.
- IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. - 2002; 359: 1269-75.
- Horinaka S., Yabe A, Yadi H. et al. Effects of nicorandil on cardiovascular events in patients with Coronary Artery Disease (JCAD) study // Circ. J. - 2010; 74: 503-9.
- Sakata Y., Nakatani D., Shimiz M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. - 2012; 59: 14-21.
- Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anadolu Kardiyol. Derg. - 2015; 15: 125-31.
- Xia F., Wang Z., Zhou Y. et al. Cerebral protective effect of nicorandil premedication on patients undergoing liver transplantation // Hepatobiliary Pancreat. Dis. Int. - 2012; 11: 132-6.
- Румянцева С.А., Оганов Р.Г, Силина Е.В. и др. Сердечнососудистая патология при остром инсульте (некоторые аспекты распространенности, профилактики и терапии) // Кардиоваск. тер. и профилакт. - 2014; 4: 47-53.
Supplementary files
